140 related articles for article (PubMed ID: 26304880)
21. Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making.
Franken MD; Koopman M; van Oijen MG
Am J Clin Oncol; 2016 Apr; 39(2):214. PubMed ID: 26999056
[No Abstract] [Full Text] [Related]
22. [Economic Evaluation of mFOLFOX6-based First-line Regimens for Unresectable Advanced or Recurrent Colorectal Cancer Using Clinical Decision Analysis].
Shida T; Endo Y; Shiraishi T; Yoshioka T; Suzuki K; Kobayashi Y; Ono Y; Ito T; Inoue T
Yakugaku Zasshi; 2018; 138(1):83-90. PubMed ID: 29311468
[TBL] [Abstract][Full Text] [Related]
23. The price tag on progress--chemotherapy for colorectal cancer.
Schrag D
N Engl J Med; 2004 Jul; 351(4):317-9. PubMed ID: 15269308
[No Abstract] [Full Text] [Related]
24. [Cost-effectiveness analysis of different chemotherapeutical regimens in metastatic colorectal cancer].
Liu TS; Yu YY; Chen YY
Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Mar; 11(2):120-3. PubMed ID: 18344076
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab in colon cancer.
Martin MJ
N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473023
[No Abstract] [Full Text] [Related]
26. A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer.
Nelson MA; Shetty S; Kulakodlu M; Harley C; Seal B
J Med Econ; 2011; 14(2):179-86. PubMed ID: 21319948
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Rivera F; Valladares M; Gea S; López-Martínez N
J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
[TBL] [Abstract][Full Text] [Related]
28. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada.
Hedden L; Kennecke H; Villa D; Johnston K; Speers C; Kovacic L; Renouf DJ; Peacock S
Eur J Cancer; 2012 Sep; 48(13):1969-76. PubMed ID: 22325838
[TBL] [Abstract][Full Text] [Related]
29. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.
Sculpher M; Palmer MK; Heyes A
Pharmacoeconomics; 2000 Apr; 17(4):361-70. PubMed ID: 10947491
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab Continuation Versus Treatment Holidays After First-Line Chemotherapy With Bevacizumab in Patients With Metastatic Colorectal Cancer: A Health Economic Analysis of a Randomized Phase 3 Trial (SAKK 41/06).
Matter-Walstra K; Schwenkglenks M; Betticher D; von Moos R; Dietrich D; Baertschi D; Koeberle D
Clin Colorectal Cancer; 2016 Dec; 15(4):314-320.e2. PubMed ID: 27117056
[TBL] [Abstract][Full Text] [Related]
31. Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis.
Norum J
J Chemother; 2006 Oct; 18(5):532-7. PubMed ID: 17127231
[TBL] [Abstract][Full Text] [Related]
32. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
Chu E; Cartwright TH
J Clin Oncol; 2008 May; 26(13):2224-6; author reply 2228. PubMed ID: 18445854
[No Abstract] [Full Text] [Related]
33. Cost considerations in the treatment of colorectal cancer.
Jansman FG; Postma MJ; Brouwers JR
Pharmacoeconomics; 2007; 25(7):537-62. PubMed ID: 17610336
[TBL] [Abstract][Full Text] [Related]
34. Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?
Okines A; Cunningham D
Eur J Cancer; 2009 Sep; 45(14):2452-61. PubMed ID: 19643598
[TBL] [Abstract][Full Text] [Related]
35. Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy.
Yajima S; Shimizu H; Sakamaki H; Ikeda S; Ikegami N; Murayama JI
BMC Health Serv Res; 2016 Jan; 16():2. PubMed ID: 26728154
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.
Riesco-Martínez MC; Berry SR; Ko YJ; Mittmann N; Giotis A; Lien K; Wong WW; Chan KK
J Oncol Pract; 2016 Jun; 12(6):e710-23. PubMed ID: 27143148
[TBL] [Abstract][Full Text] [Related]
37. Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer.
Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Harvey RD; El-Rayes BF; Flowers CR
Clin Colorectal Cancer; 2014 Dec; 13(4):219-25. PubMed ID: 25306485
[TBL] [Abstract][Full Text] [Related]
38. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
Perrocheau G; Bennouna J; Ducreux M; Hebbar M; Ychou M; Lledo G; Conroy T; Dominguez S; Faroux R; Florentin V; Douillard JY
Oncology; 2010; 79(3-4):174-80. PubMed ID: 21358204
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
Hoyle M; Peters J; Crathorne L; Jones-Hughes T; Cooper C; Napier M; Hyde C
Value Health; 2013; 16(2):288-96. PubMed ID: 23538180
[TBL] [Abstract][Full Text] [Related]
40. [Costs, disease management and DRG].
Barni S; Mandalà M; Gambera M
Tumori; 2001; 87(1 Suppl 1):S59. PubMed ID: 11300029
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]